The current study examined the use of voxel-wise changes in 18 F-FDOPA and 18 F-FLT PET uptake, referred to as parametric response maps (PRMs), to determine whether they were predictive of response to bevacizumab in patients with recurrent malignant gliomas. Twenty-four patients with recurrent malignant gliomas who underwent bevacizumab treatment were analyzed. Patients had MR and PET images acquired before and at 2 time points after bevacizumab treatment. PRMs were created by examining the percentage change in tracer uptake between time points in each image voxel. Voxel-wise increase in PET uptake in areas of pretreatment contrast enhancement defined by MRI stratified 3-month progression-free survival (PFS) and 6-month overall survival (OS) according to receiveroperating characteristic curve analysis. A decrease in PET tracer uptake was associated with longer PFS and OS, whereas an increase in PET uptake was associated with short PFS and OS. The volume fraction of increased 18 F-FDOPA PET uptake between the 2 posttreatment time points also stratified long-and short-term PFS and OS (log-rank, P < .05); however, 18 F-FLT uptake did not stratify OS. This study suggests that an increase in FDOPA or FLT PET uptake on PRMs after bevacizumab treatment may be a useful biomarker for predicting PFS and that FDOPA PET PRMs are also predictive of OS in recurrent gliomas treated with bevacizumab.
M alignant gliomas (World Health Organization
[WHO] grades III -IV) are primary central nervous system (CNS) tumors with a poor patient prognosis. Malignant gliomas constitute approximately 70% of all neuroepithelial tumors and approximately 23% of all primary CNS tumors. 1 Despite new therapies, the median survival time for patients with malignant gliomas has improved only marginally. Bevacizumab, a humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), is now the standard of care for recurrent malignant gliomas, including glioblastoma. 2 Treatment with bevacizumab has shown to be effective in extending progression-free survival in patients with glioblastoma; 3 however, only a few biomarkers are available for predicting the response of recurrent malignant gliomas to bevacizumab therapy. 4 -9 Positron emission tomography (PET) imaging using [ 18 F]-fluorodeoxyglycose (FDG) is the most commonly used radiotracer method for examining metabolic activity of malignant tumors. Despite its widespread use in oncology, FDG often provides relatively poor contrast in the brain between background tissue and tumor because of high uptake in normal brain tissue. 10 [ 18 F]-fluoro-3-deoxy-3-L-fluorothymidine ( 18 F-FLT), a thymidine analog that is a surrogate marker for DNA synthesis based on the activity of thymidine kinase-1, has shown value in directly quantifying tumor cell proliferation. 11 Although the absolute uptake in tumor regions is typically lower for 18 F-FLT than for 18 Ffluorodeoxyglucose ( 18 F-FDG), the relative contrast between tumor and normal tissue is higher for 18 F-FLT and has been shown to be more sensitive than 18 F-FDG for evaluating recurrent high-grade gliomas. 11 3,4-dihydroxy-6-[
18 F]-fluoro-L-phenylalanine ( 18 F-FDOPA) is an amino acid analog. Similar to 18 F-FLT, 18 F-FDOPA has also shown improved contrast between tumor and normal brain tissue in patients with high-grade glioma because of elevated amino acid transportation in malignant tumor cells. 12 We hypothesized that voxel-wise changes in 18 F-FDOPA and 18 F-FLT uptake, or parametric response maps (PRMs), in the same patient across multiple time points would be predictive of response in patients with recurrent glioblastoma treated with bevacizumab, as measured by progression-free (PFS) and overall survival (OS). Furthermore, we hypothesized that the combination of 18 F-FDOPA and 18 F-FLT would be synergistically prognostic, because the biological mechanisms of tracer uptake are fundamentally different.
To test these hypotheses, PET PRMs were constructed for both 18 F-FDOPA and 18 F-FLT for each patient in regions of contrast enhancement defined by magnetic resonance imaging (MRI). PRMs were calculated by examining the change in PET uptake before and after initial bevacizumab treatment, along with the change in PET uptake between the 2 time points after initiation of bevacizumab treatment.
Materials and Methods

Patients
All patients in this study signed institutional review board -approved informed consent to have their data collected and stored in our institution's neuro-oncology database. Data from 24 patients with malignant gliomas (WHO grade IV, n ¼ 18; WHO grade III, n ¼ 6) who were previously examined in separate studies using circular regions of interest and placed in the highest tumor standard uptake value (SUV) 13, 14 were retrospectively analyzed for the current study. All patients were treated with bevacizumab, and all but 2 received a supplemental chemotherapeutic agent (irinotecan). Of the 24 patients in the study, 18 F-FDOPA data was acquired for 23, 18 F-FLT data was acquired for 21, and 20 received both 18 F-FDOPA and 18 F-FLT scans. PET time points were taken within 1 week before the start of bevacizumab treatment, 1 -2 weeks after treatment, and 5-7 weeks after the start of treatment (Fig. 1 ).
18
F-FDOPA and 18 F-FLT scans were obtained within 1-2 days at each time point in patients with both scans, and the order of PET scan acquisition was randomized at each follow-up time.
PET
18
F-FDOPA images were acquired and processed using methods similar to those previously described. 15 -17 18 F-FDOPA was synthesized according to standard procedures 18, 19 and injected at a dose of 1.1 -6.6 MBq/kg body weight. 18 F-FLT was synthesized locally using previously described methods, 20 and 18 F-FLT images were acquired and processed using techniques similar to those previously described. 13 For both 18 F-FDOPA and 18 F-FLT images, a transmission scan was obtained for attenuation correction. 21 18 F-FDOPA emission data were acquired in 3-dimensional mode 10 min after injection for a total of 30 min. Data collected at 10 -30 min were summed to obtain a 20-min static 18 F-FDOPA image after reconstruction as previously described. 18 F-FLT emission data were collected in 3-dimensional mode immediately after injection for a total of 60 min. Data collected at 30 -60 min were summed to obtain a 30-min static 18 F-FLT image and reconstructed as previously described. All images for both 18 F-FDOPA and 18 F-FLT were obtained using a high-resolution full-ring PET scanner (ECAT HR+; Siemens/CTI).
MRI
Data were collected on a 1.5T MR system (General Electric Medical Systems or Siemens Medical) using pulse sequences supplied by the scanner manufacturer. 5, 22 Any PRM voxel value outside of the 95% confidence interval was classified as a significant increase or decrease in PET tracer uptake.
Region of Interest (ROI) Selection
The current study focused on using contrast enhancing regions on pretreatment, postcontrast T1-weighted images for subsequent PRM analysis. Regions of T2 or FLAIR signal abnormality are thought to encompass the largest extent of malignant infiltrating tumor; 23 -27 however, these regions also contain a large fraction of edematous tissue and have traditionally had worse clinical sensitivity than regions of contrast enhancement when evaluating response to bevacizumab. 4 Therefore, regions of contrast enhancement on pretreatment postcontrast images were used in the current study to isolate PRM analysis to regions believed to contain the most aggressive tumor. 28 -33 Regions of contrast enhancement are largely accepted as the best measure of tumor burden, because they are used in both standard radiographic assessment (i.e., Macdonald criteria 34 ) and the new Response Assessment in Neuro-Oncology assessment. 35 A semiautomated thresholding technique described previously was used to mask the pretreatment contrast-enhancing lesion for each patient. 6 For each PET PRM (4 per patient consisting of a Pre/Post 
Definition of Disease Progression
Progression was defined prospectively by the treating neuro-oncologists. If subsequent scans showed definite increase in imaging-evaluable tumor (≥25% increase in the sum of enhancing lesions, new enhancing lesions .1 cm 2 , or an unequivocal qualitative increase in nonenhancing tumor or unequivocal new area of noncontrast enhancing tumor), progression was declared at that time. Change in steroid dosage was taken into consideration while defining progression. Patients who did not meet these imaging criteria for progression but had significant neurologic decline were declared to have progressed at the time of irreversible decline. Patients who died before evidence of imaging progression were defined to have progressed on the date of death. PFS was defined as the time from the start of bevacizumab treatment to radiographic and/or clinical progression. OS was defined as the interval from the start of bevacizumab treatment to patient death.
Hypothesis Testing
Receiver-operating characteristic (ROC) analysis was performed on PET PRM measurements and change in the volume of contrast enhancement on post-contrast T1-weighted images to determine the sensitivity and specificity of detecting 3-month PFS and 6-month OS. Area under the curve (AUC) was used as a measure of PET PRM performance. In addition, survival analysis was performed using log-rank statistical analysis of Kaplan-Meier data. All statistical tests were performed using GraphPad Prism, version 4.0 (GraphPad Software).
Results
After normalization of each PET SUV image to the mean uptake in NAWM, voxel-wise changes in 18 F-FDOPA and 18 F-FLT in NAWM were quantified to evaluate for temporal stability. The 95% confidence interval for voxel-wise changes in normalized NAWM was 214.5% to +14.5% between the pre-and posttreatment time points and 213.5% to +14.5% between the 2 posttreatment time points ( Fig. 2A) , whereas the 95% confidence interval for voxel-wise changes in normalized 18 F-FLT was 229.6% to +34.6% between the pre-and posttreatment time points and 228.6% to +38.7% between the 2 posttreatment time points (Fig. 2B) . These confidence intervals were then used for production of 18 F-FDOPA and 18 F-FLT PET PRMs. (Note that the confidence intervals for 18 F-FLT PRMs were slightly asymmetric, biased slightly to a subtle decrease in tracer uptake between the different time points.)
Qualitatively, initial administration with bevacizumab resulted in reduction of both contrast enhancement and T2-weighted signal abnormality for most patients. Similarly, 18 F-FDOPA and 18 F-FLT showed a significant decrease in uptake for the same patients after initial administration of bevacizumab. Between the 2 posttreatment time points, the change in 18 F-FDOPA and 18 F-FLT uptake varied, with some patients showing stable or further decreasing levels of uptake, whereas other patients had increased uptake between the 2 posttreatment time points. Patients exhibiting continued decrease in 18 F-FDOPA or 18 F-FLT uptake in contrast enhancing regions on normalized PET PRMs appeared to be more likely to progress later and live longer (Fig. 3) , compared with patients with increased uptake (Fig. 4) .
ROC Performance for Predicting 3-Month PFS and 6-Month OS
ROC analysis was performed for each PET PRM metric, along with change in the volume of contrast F-FDOPA uptake within NAWM, suggesting the 95% confidence interval ranged from 214.5% to +14.5% (Pre/Post) and 213.5% to +14.5% (Post1/Post2). (B) Histogram of voxel-wise changes in 18 F-FLT uptake within NAWM, suggesting the 95% confidence interval ranged from 229.6% to +34.6% (Pre/Post) and 228.6% to 38.7% (Post1/Post2). enhancement on postcontrast T1-weighted MR images, to determine sensitivity and specificity for predicting 3-month PFS and 6-month OS. Performance of each PET PRM metric for each end point is summarized in Tables 1-4 . In general, ROC analysis suggested that a decrease in contrast enhancement of .5cc on MRI before and after treatment was a good predictor of both longer time to progression and overall survival 18 F-FLT had slightly less specificity for 3-month PFS and 6-month OS than did 18 F-DOPA, although overall ROC performance suggested similar trends. Of importance, the volume (and volume fraction) required for 18 F-FLT PRMs to predict response was much lower than that required for 18 F-FDOPA PRMs. Specifically, the volume fraction of changing voxels in 18 F-FLT PRMs evaluated before and after bevacizumab therapy was a significant predictor of 3-month PFS (Table 3;  Fig. 5A; Threshold ¼ 70%, Sensitivity ¼ 90%, Specificity ¼ 70%, AUC ¼ 0.78, P ¼ .0218). The volume of tissue with decreasing 18 F-FLT uptake within regions of contrast enhancing regions on 18 F-FLT PRMs was also a significant predictor of 3-month PFS (Table 3 ; Fig. 5A ; Threshold ¼ 2cc, Sensitivity ¼ 78%, Specificity ¼ 78%, AUC ¼ 0.81, P ¼ .0244). In addition, increased 18 F-FLT uptake in pretreatment contrast-enhancing regions on PRMs evaluated before and after treatment with bevacizumab was a significant predictor of 6-month OS (Table 4 ; Fig. 5B ;
To evaluate the potential synergy of combining information from both F-FDOPA and 18 F-FLT before and after bevacizumab therapy was a significant predictor of 3-month PFS ( Fig. 5C ; Threshold ¼ 1cc total volume, Sensitivity ¼ 78%, Specificity ¼ 77%, AUC ¼ 0.80, P ¼ .018) but not a predictor of 6-month OS (ROC AUC ¼ 0.61, P ¼ .413). Similarly, the total volume of changing 18 F-FDOPA and 18 F-FLT uptake before and after bevacizumab therapy ( Fig. 5C ; Threshold ¼ 25cc, Sensitivity ¼ 78%, Specificity ¼ 85%, AUC ¼ 0.79, P ¼ .021), the total volume of decreasing 18 F-FDOPA and 18 F-FLT between the 2 postbevacizumab therapy scans ( Fig. 5C ; Threshold ¼ 8cc, Sensitivity ¼ 78%, Specificity ¼ 69%, AUC ¼ 0.75, P ¼ .049), and the product of the volume fraction of decreasing 18 F-FDOPA and 18 F-FLT uptake between the 2 post-bevacizumab therapy scans ( Fig. 5C ; Threshold ¼ 5%, Sensitivity ¼ 50%, Specificity ¼ 95%, AUC ¼ 0.77, P ¼ .035) were significant predictors of 3-month PFS but not 6-month OS.
Survival Analysis
18
F-FDOPA PET PRMs were able to stratify patients based on both PFS and OS. In particular, patients exhibiting an increase in 18 F-FDOPA uptake .0.35cc (median volume), or 2.5% (median percentage of enhancing tumor), on PRMs from data before and after 18 F-FDOPA uptake .5.7% (median) on PRMs from data between the follow-up scans after the initial bevacizumab dose, however, were at risk for shorter PFS and OS ( Fig. 6A ; PFS, Log-rank, P ¼ .0182; Fig. 5B ; OS, Log-rank, P ¼ .0111).
Log-rank analysis on Kaplan-Meier data suggested a volume fraction of increasing 18 F-FLT uptake on PRMs evaluated between the 2 follow-up posttreatment time points .10% resulted in a statistically shorter PFS ( Fig. 6C ; %Vol(+)
FLT , Log-rank, P ¼ .0035); however, there was no significant difference in OS between these groups. Combined response of 18 F-FDOPA and 18 F-FLT PET PRMs allowed for significant separation of PFS using a threshold of 15% ( Fig. 6D; 
Discussion
Results from the current study suggest that a large volume (or volume fraction) of increased 18 F-FDOPA or 18 F-FLT uptake on PRMs evaluated between the 2 follow-up time points after initial administration of bevacizumab treatment were associated with a shortened PFS, compared with patients with a sustained decrease in uptake after treatment. Decreased uptake in both tracers appeared to provide a high sensitivity but low specificity for predicting 3-month PFS and 6-month OS; conversely, increased uptake was associated with a high specificity and low sensitivity for predicting these same end points. Log-rank analysis revealed, however, that only 18 F-FDOPA PRM measurements taken using the 2 posttreatment time points were a statistically significant predictor of OS.
Of note, test-retest reliability of PET tracers in the current study were consistent with previous studies examining PET uptake in normal structures, suggesting that results obtained in the current study may be applicable at other clinical sites. For example, 18 F-FDOPA PET uptake in normal individuals has been estimated at approximately 8%. 36 Assuming that 18 F-FDOPA SUVs follow a normal distribution, this 8% standard deviation results in a 95% confidence interval for change in 18 F-FDOPA SUV of approximately 15%, consistent with estimates in the current study of approximately 14.5%. Standard deviation in 18 F-FLT SUV uptake, however, has been estimated to be as high as 15%. 37, 38 A standard deviation this high results in a 95% confidence interval for 18 F-FLT of nearly 30%, consistent with the voxel-wise 95% confidence interval for NAWM of approximately 30%. Together, these results suggest that the inherent variability in 18 F-FDOPA uptake may be slightly less than that of 18 F-FLT PET, which may explain the superior performance of 18 F-FDOPA PRMs, compared with 18 F-FLT PRMs. Of importance, however, the volume (and volume fraction) required for 18 F-FDOPA PRMs to predict response was greater than that required for 18 F-FLT. Similar to results from the current study, other voxelwise biomarkers have shown the ability to predict response to bevacizumab in recurrent malignant gliomas, including the use of functional diffusion maps (fDMs), 4 cell invasion, motility, proliferation level estimate (CIMPLE) maps, 7 and differential quantitative T2 (DQT2) maps. 5 Studies examining fDMs and DQT2 demonstrated significant changes in the apparent diffusion coefficient (ADC) and T2 relaxation rate, which was largely attributed to changes in vascular permeability and edema. CIMPLE maps, which were evaluated after administration of bevacizumab, were thought to more closely reflect changes in cell proliferation rate rather than changes in edema. It is conceivable that the large decrease in tracer uptake observed before and after initial administration of bevacizumab in the current study was attributable to the change in vascular permeability or perfusion, whereas the change in tumor uptake between the 2 posttreatment follow-up time points more closely reflected changes in tumor metabolism and proliferation. Muzi et al. 39 clearly demonstrated the dependence of 18 F-FLT uptake rate (i.e., K 1 ) on vascular permeability; however, studies have shown that 18 F-FDOPA uptake rate may not reflect simple tracer diffusion because of disruption of the blood-brain barrier but, instead, likely reflects the rate of carrier-mediated facilitated transportation. 40 In direct contrast with the notion that the effects found in the current study were directly attributable to changes in permeability, we observed regions of increased and decreased PET uptake in areas of residual contrast enhancement after treatment with bevacizumab. Despite this evidence, future studies examining the effects of vascular permeability on 18 F-FDOPA and 18 F-FLT uptake are warranted.
Although both MRI and PET may be predictive of response to therapy, they provide dramatically different information about tumor biology. Although a change in contrast-enhancing volume as a result of therapy was predictive of PFS and OS, a change in PET uptake on subsequent time points (excluding the potential confounds from vascular permeability) was a better predictor of PFS. These results suggest that MRI and PET features are distinctly different and are both potentially valuable. Of note, although change in contrast-enhancing volume before and after bevacizumab treatment was predictive of 3-month PFS, progression was at least partially defined by contrast enhancement via MRI, potentially introducing bias into this type of analysis. Furthermore, the study performed by Schwarzenberg et al, 13 which used the same patients but evaluated using ROI analysis, also found that MRI was predictive of PFS and OS; however, PET analysis provided increased predictive power, compared with MRI alone.
Previous studies have shown that changes in 18 F-FLT SUV are a useful tool for predicting PFS and OS in recurrent malignant gliomas treated with bevacizumab; 13, 14 however, static SUV measurements at a single time point were not predictive of response. Similar to these studies, the PRM technique applied to 18 F-FLT data was able to stratify patients according to PFS and provided more localized qualitative information of changes in tracer uptake around the tumor region. The current study, however, did not find a statistical relationship between 18 F-FLT uptake and OS when using the Kaplan-Meier analysis. This is likely to be attributable to the relatively wide confidence intervals for voxel-wise change in 18 F-FLT uptake in NAWM, compared with 18 F-FDOPA uptake (Fig. 2) . This high variability resulted in fewer voxels being categorized as significantly increasing or decreasing and may have lowered the overall sensitivity of this biomarker for stratifying OS. Future studies aimed at either reducing this variability or using a different confidence interval for 18 F-FLT PRMs may be necessary for improving performance of this biomarker.
In addition to 18 F-FLT, kinetic parameters and uptake measured by SUVs of 18 F-FDOPA have been previously studied for the prediction of tumor grade and proliferative activity in glioblastoma. 12, 15, 41, 42 However, to our knowledge, 18 F-FDOPA has not previously been tested for predictive capabilities of PFS and OS among patients with recurrent malignant gliomas treated with bevacizumab. The current study demonstrates that voxel-wise changes in 18 F-FDOPA provided higher sensitivity and specificity for predicting 3-month PFS and 6-month OS and allowed statistically significant separation of shortand long-term PFS and OS using log-rank analysis.
Although the current study used 18 F-FDOPA and 18 F-FLT PET images to predict the response to recurrent malignant gliomas treated with bevacizumab, other PET tracers have also shown promise for predicting response to anti-angiogenic therapy. For example, a recent study by Colavolpe et al. 43 clearly demonstrated the prognostic ability of baseline, pretreatment 18 F-FDG maximum SUV to predict the response to bevacizumab and irinotecan therapy in malignant gliomas, supporting the hypothesis that 18 F-FDG uptake is strongly correlated with angiogenesis markers in gliomas. 44 Median 18 F-FDG SUV in contrast-enhancing regions, normalized to gray matter, at 4 weeks posttreatment has also been shown to be a significant prognostic factor in anaplastic gliomas treated with single-agent bevacizumab; 45 however, this study did not find baseline or change in 18 F-FDG PET uptake to be particularly predictive of patient response. On the basis of these somewhat conflicting results, which are likely to be attributable to different definitions of 18 F-FDG uptake and slightly different patient populations, we hypothesize that 18 F-FDG PET PRMs may also be useful for assessing malignant glioma response to bevacizumab.
Study Limitations
One inherent source of error in PRM analysis is imperfect registration between MR and PET images acquired separately and with registration of MR and PET images in the same patient over multiple time points. This misregistration is often attributable to mass effect related to tumor growth. Another potential source of error is the normalization process. Specifically, normalization of PET activity values based on contralateral white matter may have skewed our results because of inter-patient variations in local tracer uptake. Our investigations suggested that a form of normalization was necessary, because we found a significant difference in SUV value in regions of NAWM in the same patient over time. By normalizing to the SUV in NAWM, the variability of measurements in normal regions in brain for the same patient across time was largely reduced, allowing us to more accurately characterize subtle changes in tracer uptake in the tumor regions.
As has been demonstrated in 18 F-FDOPA evaluation of patients with movement disorders affecting the striatal dopamine pathway, 46 ,47 the basal ganglia has intrinsic uptake of 18 F-FDOPA through neutral amino acid transporters. 48 Thus, 18 F-FDOPA PET may have an inherent limitation for evaluation of subcortical tumors near the basal ganglia. However, 18 F-FDOPA PET PRMs quantify the change in 18 F-FDOPA uptake in tumor regions; therefore, this potential limitation may not be substantial.
Lastly, we chose to use regions of contrast enhancement on postcontrast MR images prior to treatment with bevacizumab as regions of interest for the current analysis. Previous studies suggested that regions of FLAIR signal abnormality may also be beneficial to examine, because FLAIR regions may contain metabolically active areas of nonenhancing tumor. Although not shown in the current study, PRM analysis of PET tracers in FLAIR regions was largely not informative beyond that of postcontrast ROIs. Future studies aimed at improving these limitations are necessary to fully understand the capabilities of quantitative PET PRMs.
Conclusion
The current study examined retrospective 18 F-FDOPA and 18 F-FLT PET data collected from 24 patients with recurrent malignant gliomas treated with bevacizumab to construct voxel-wise PET PRMs. PRMs provided a visual and quantitative assessment of regional changes in PET uptake and prognostic information about PFS based on change in tracer uptake during the weeks after treatment. Despite these promising findings, we observed only a weak relationship between PRM response and OS. These results suggest that 18 F-FDOPA and 18 F-FLT PET PRM may be valuable imaging biomarkers for predicting PFS in recurrent malignant gliomas treated with bevacizumab.
